Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes.

Nanchen, David; Gencer, Baris; Auer, Reto; Räber, Lorenz; Stefanini, Giulio; Klingenberg, Roland; Schmied, Christian M; Cornuz, Jacques; Muller, Olivier; Vogt, Pierre; Jüni, Peter; Matter, Christian M; Windecker, Stephan; Lüscher, Thomas F; Mach, François; Rodondi, Nicolas (2015). Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. European Heart Journal, 36(36), pp. 2438-2445. Oxford University Press 10.1093/eurheartj/ehv289

[img] Text
Nanchen EurHeartJ 2015.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (291kB) | Request a copy
[img]
Preview
Text
ehv289.pdf - Other
Available under License Publisher holds Copyright.

Download (291kB) | Preview

AIMS We aimed to assess the prevalence and management of clinical familial hypercholesterolaemia (FH) among patients with acute coronary syndrome (ACS). METHODS AND RESULTS We studied 4778 patients with ACS from a multi-centre cohort study in Switzerland. Based on personal and familial history of premature cardiovascular disease and LDL-cholesterol levels, two validated algorithms for diagnosis of clinical FH were used: the Dutch Lipid Clinic Network algorithm to assess possible (score 3-5 points) or probable/definite FH (>5 points), and the Simon Broome Register algorithm to assess possible FH. At the time of hospitalization for ACS, 1.6% had probable/definite FH [95% confidence interval (CI) 1.3-2.0%, n = 78] and 17.8% possible FH (95% CI 16.8-18.9%, n = 852), respectively, according to the Dutch Lipid Clinic algorithm. The Simon Broome algorithm identified 5.4% (95% CI 4.8-6.1%, n = 259) patients with possible FH. Among 1451 young patients with premature ACS, the Dutch Lipid Clinic algorithm identified 70 (4.8%, 95% CI 3.8-6.1%) patients with probable/definite FH, and 684 (47.1%, 95% CI 44.6-49.7%) patients had possible FH. Excluding patients with secondary causes of dyslipidaemia such as alcohol consumption, acute renal failure, or hyperglycaemia did not change prevalence. One year after ACS, among 69 survivors with probable/definite FH and available follow-up information, 64.7% were using high-dose statins, 69.0% had decreased LDL-cholesterol from at least 50, and 4.6% had LDL-cholesterol ≤1.8 mmol/L. CONCLUSION A phenotypic diagnosis of possible FH is common in patients hospitalized with ACS, particularly among those with premature ACS. Optimizing long-term lipid treatment of patients with FH after ACS is required.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine > Centre of Competence for General Internal Medicine
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine
04 Faculty of Medicine > Pre-clinic Human Medicine > CTU Bern
04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology

UniBE Contributor:

Räber, Lorenz; Stefanini, Giulio; Jüni, Peter; Windecker, Stephan and Rodondi, Nicolas

Subjects:

600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services

ISSN:

0195-668X

Publisher:

Oxford University Press

Language:

English

Submitter:

Doris Kopp Heim

Date Deposited:

26 Nov 2015 15:20

Last Modified:

21 Sep 2018 02:30

Publisher DOI:

10.1093/eurheartj/ehv289

PubMed ID:

26142466

Uncontrolled Keywords:

Familial hypercholesterolaemia; acute coronary syndrome; cardiovascular prevention; premature atherosclerosis; quality of care

BORIS DOI:

10.7892/boris.73442

URI:

https://boris.unibe.ch/id/eprint/73442

Actions (login required)

Edit item Edit item
Provide Feedback